Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.40 |
| ▸ | CHRM2 known ✓ | P08172 | 4/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.39 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.37 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.37 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.37 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.37 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.37 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.37 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.37 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.37 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.37 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.37 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.37 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL26105242 | 1.00 | SLC6A12 (0.42) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| Hydrochloric Acid SCHEMBL23406281 | 1.00 | SLC6A12 (0.42) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL21063808 | 0.98 | CHRNA7 (0.41) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL21063738 | 0.98 | CHRNA7 (0.41) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL4280104 | 0.98 | CHRNA7 (0.41) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL29271818 | 0.96 | CHRNA7 (0.40) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL21095754 | 0.88 | SLC6A12 (0.39) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL21095889 | 0.88 | SLC6A12 (0.39) | SLC6A12SLC6A11SLC6A13CHRNA7CHRM2 | |
| SCHEMBL660508 | 0.80 | CHRNA7 (0.45) | CHRNA7CHRM2CYP2D6CHRM1MEN1 | |
| SCHEMBL6573447 | 0.80 | CHRNA7 (0.45) | CHRNA7CHRM2CYP2D6CHRM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250281419-A1 | LIPID AMINES | ARES CAPITAL CORPORATION, AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-3673906-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-4429644-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ModernaTX, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4423108-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | ARES CAPITAL CORPORATION, AS AGENT | 2023-09-14 | — | — | US | disclosed |
| WO-2023154818-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-1458717-A1 | AROYL PYRIDINONES | Bayer HealthCare AG (DE) | 2004-09-22 | — | — | EP | disclosed |
| EP-1452534-A1 | PLEUROMUTLIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003053967-A1 | AROYL PYRIDINONES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
| EP-0934316-B1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 2002-10-16 | — | — | EP | disclosed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | disclosed |
| US-6121281-A | Azabicyclic carbamoyloxy mutilin derivatives for antibacterial use | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-09-19 | — | — | US | disclosed |
| EP-1028961-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-23 | — | — | EP | disclosed |
| EP-0934316-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1999021855-A1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998005659-A1 | AZABICYCLIC CARBAMOYLOXY MUTILIN DERIVATIVES FOR ANTIBACTERIAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049727-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | CHRNA7 3402/4885CHRM2 4595/4885CHRM1 4710/4885 |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | CHRNA7 1619/4885CHRM2 3869/4885CHRM1 4242/4885 |
| US-20230285310-A1 | COMPOSITIONS FOR THE DELIVERY OF PAYLOAD MOLECULES TO AIRWAY EPITHELIUM | CFTR, TSLP, MTREX | CHRNA7 3402/4885CHRM2 4595/4885CHRM1 4710/4885 |
| US-20250281419-A1 | LIPID AMINES | SGMS1, PHOSPHO1, SGMS2 | CHRNA7 1202/4885CHRM2 529/4885CHRM1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.